A new pancreatic cancer drug called daraxonrasib cut the risk of death by 60% in a Phase 3 trial. What it is, how it works, side effects and when it could reach patients.
Continue Reading
News Source: www.forbes.com
A new pancreatic cancer drug called daraxonrasib cut the risk of death by 60% in a Phase 3 trial. What it is, how it works, side effects and when it could reach patients.
News Source: www.forbes.com
Leave a Reply